IMMUCELL CORP. DL-,10

ImmuCell posted Q2 product sales up 11.5% year‑over‑year to $7.2 million and net income of $1.8 million, driven by a 27.7% rise in domestic sales that offset a 38.9% drop in international revenue. First Defense/Tri‑Shield volumes and U.S. market share increased, with distributor out‑the‑door volumes up ~24% in the first half. Management said margins were hit by lower production output, scrap and recurring costs tied to the discontinued Re‑Tain program. The company plans roughly $8 million of investments in freeze‑drying and liquids processing to more than triple capacity and shorten processing times by end of 2027. » More on finance.yahoo.com

ImmuCell reports preliminary Q2 revenue of $7.2 million, up 11.5% year over year. Domestic sales rose 27.7% to $6.2 million, while international sales fell 38.9% to $1.0 million. Tri‑Shield First Defense generated $4.9 million in revenue (+8.3%); Dual‑Force and other products contributed $2.3 million (+19.1%). Half‑year revenue totaled $17.5 million (+20.9%). The stock is trading near its 52‑week high, and the board notes a difficult comparison base with Q2 2025. Full results will be released on August 14. » More on de.investing.com

At the virtual annual meeting on June 11, ImmuCell shareholders voted to elect seven directors and approved all submitted proposals, including the non-binding approval of executive compensation, the 2025 stock option and incentive plan, and a charter amendment for Delaware indemnification. Wipfli was confirmed as the independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. The meeting saw participation by over 81% of the voting shares. ImmuCell also reported strong Q1 results with $10 million in revenue and EPS of $0.21 (+34% year-over-year), which supported the stock in pre-market trading; the shares are up about 54% over the past six months and are trading at $9.49. » More on de.investing.com